scholarly article | Q13442814 |
P50 | author | Fabio Mangiacapra | Q40625497 |
Emanuele Barbato | Q42844569 | ||
Germano Di Sciascio | Q59188165 | ||
William Wijns | Q61278410 | ||
Catalina Trana | Q87635928 | ||
Guy R Heyndrickx | Q90553844 | ||
Olivier Muller | Q102144464 | ||
Bernard De Bruyne | Q114304193 | ||
Jozef Bartunek | Q114309811 | ||
Argyrios Ntalianis | Q114411817 | ||
P433 | issue | 1 | |
P921 | main subject | atherosclerosis | Q12252367 |
myocardial infarction | Q12152 | ||
clopidogrel | Q410237 | ||
stable angina | Q3617336 | ||
P304 | page(s) | 35-40 | |
P577 | publication date | 2010-01-01 | |
P1433 | published in | JACC: Cardiovascular Interventions | Q15816248 |
P1476 | title | High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention | |
P478 | volume | 3 |
Q37989558 | A contemporary viewpoint on 'aspirin resistance'. |
Q36371663 | Adenosine A2A receptor agonists with potent antiplatelet activity. |
Q38070127 | Clinical implications of platelet-vessel interaction |
Q33760816 | Correlations between High Platelet Reactivity, Extent of Coronary Artery Disease, and Periprocedural Myonecrosis in Patients with Acute Coronary Syndrome |
Q37605071 | Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients |
Q54722997 | Double-blind parallel placebo-controlled study to evaluate the effect of molsidomine on the endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: the MEDCOR Trial. |
Q50085829 | Effect of Chewing vs Swallowing Ticagrelor on Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial. |
Q30450312 | High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study |
Q37203987 | Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome |
Q49948271 | Impact of platelet reactivity on 5-year clinical outcomes following percutaneous coronary intervention: a landmark analysis |
Q38071262 | Influence of platelet reactivity on clinical outcome of patients with stable coronary artery disease. |
Q46211908 | Lack of correlation between platelet reactivity and glycaemic control in type 2 diabetes mellitus patients treated with aspirin and clopidogrel |
Q38073160 | Novel antiplatelet agents: ALX-0081, a Nanobody directed towards von Willebrand factor |
Q61651390 | Optimizing Revascularization Strategies in Coronary Artery Disease for Optimal Benefit to Patients |
Q51594125 | PREDICT score and CYP2C19 polymorphism independently predict lack of efficacy of clopidogrel in cardiology patients. |
Q57097673 | Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention |
Q39433616 | Platelet oxidative stress as a novel target of cardiovascular risk in frail older people. |
Q37765291 | Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization |
Q45710775 | St. John's Wort in patients non-responders to clopidogrel undergoing percutaneous coronary intervention: a single-center randomized open-label trial (St. John's Trial). |
Q38375641 | Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2-Hour Infusion in High-Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention |
Q61651374 | von Willebrand Factor Inhibition Improves Endothelial Function in Patients with Stable Angina |
Search more.